Development of acute lung injury and ILD in non-small cell lung cancer (NSCLC) patients receiving gefitinib demonstrates possible deleterious effects of the ErbB1 signaling inhibition [78,79]. This evidence concerns the gene EGFR and interstitial lung disease.